Theradiag: 7% growth in half-year sales
Growth accelerated slightly in the second quarter of 2023, thanks to good sales performances in both Theradiag business lines (+9.4% for theranostics and +5.3% for in vitro diagnostics).
"On the strength of a comfortable cash position, we intend to pursue the development and accelerate the marketing of our high-margin, in-house-manufactured products over the coming months", says CEO Simon Davière.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction